Can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive sampling

One of the most important benign tumors in neurofibromatosis type 1 (NF1) is plexiform neurofibroma, and there is a risk of developing malignant peripheral nerve sheath tumor (MPNST) throughout life approximately 10%. However lesion characterization by anatomical imaging methods are not possible. Be...

Full description

Saved in:
Bibliographic Details
Main Authors: Fikri Selcuk Simsek, Saadet Akarsu, Yavuz Narin
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2019-01-01
Series:World Journal of Nuclear Medicine
Subjects:
Online Access:http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_11_18
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850230745808764928
author Fikri Selcuk Simsek
Saadet Akarsu
Yavuz Narin
author_facet Fikri Selcuk Simsek
Saadet Akarsu
Yavuz Narin
author_sort Fikri Selcuk Simsek
collection DOAJ
description One of the most important benign tumors in neurofibromatosis type 1 (NF1) is plexiform neurofibroma, and there is a risk of developing malignant peripheral nerve sheath tumor (MPNST) throughout life approximately 10%. However lesion characterization by anatomical imaging methods are not possible. Because of that most of cases goes to biopsy. Using of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) for lesion characterization can be helpful in NF1 patients. We aimed to present an example of the efficacy of FDG-PET/CT in distinguishing benign neurofibroma from MPNST. A 6-year-old male patient who had NF1 admitted to emergency service due to high fever. Acute upper respiratory tract infection was diagnosed; antipyretic and abundant fluid intake was suggested. When high fever continued, the patient referred to our hospital on detection of axillary lymphadenopathy. Leukocytosis was detected in patient's blood count. Sedimentation was 54 mm/h, C-reactive protein 166 g/L, and lactate dehydrogenase 276U/L. Blood and throat cultures did not show pathogenic bacteria. In serological tests, VZV-IgG, EBV-VCA-IgG, and CMV-IgG were avidite positive; Hepatitis B Ag, Anti-HIV, Anti-HAV IgG and IgM, Anti-HCV, EBV-VCA IgM, and VZV-IgM were negative. Based on these results, cervical and thoracic contrast-enhanced computed tomography was performed on preliminary diagnosis of MPNST. Solid lesions with rounded margins, large one being 49 mm in size, that extend from superior mediastinum to posterior mediastinum, left axillary region, and left part of neck were detected, and they were surrounding the vascular structures. Since neurofibroma, MPNST, and lymphoma could not be distinguished, patient referred to FDG-PET/CT scanning. In FDG-PET/CT, highest lesion maximum standardized uptake value (SUVmax) was 1.5; SUVmaxlesion/SUVmaxliver 1.0, and SUVmax/ SUV mean liver 1.5. Biopsy from mediastinal and axillary region did not have LN structure and was positive for S-100 immunostaining, and patient was diagnosed as benign neurofibroma. We believe that there is no need for biopsy in lesions considered benign based on FDG-PET/CT parameters.
format Article
id doaj-art-e9c5a5564d4b43399bfa2d8807e6559b
institution OA Journals
issn 1450-1147
1607-3312
language English
publishDate 2019-01-01
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
record_format Article
series World Journal of Nuclear Medicine
spelling doaj-art-e9c5a5564d4b43399bfa2d8807e6559b2025-08-20T02:03:46ZengThieme Medical and Scientific Publishers Pvt. Ltd.World Journal of Nuclear Medicine1450-11471607-33122019-01-011801666810.4103/wjnm.WJNM_11_18Can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive samplingFikri Selcuk Simsek0Saadet Akarsu1Yavuz Narin2Department of Nuclear Medicine, Firat University Medical Faculty, Elazığ, TurkeyDepartment of Paediatric Oncology, Firat University Medical Faculty, Elazığ, TurkeyDepartment of Nuclear Medicine, Elazig Medical Park Hospital, Elazığ, TurkeyOne of the most important benign tumors in neurofibromatosis type 1 (NF1) is plexiform neurofibroma, and there is a risk of developing malignant peripheral nerve sheath tumor (MPNST) throughout life approximately 10%. However lesion characterization by anatomical imaging methods are not possible. Because of that most of cases goes to biopsy. Using of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) for lesion characterization can be helpful in NF1 patients. We aimed to present an example of the efficacy of FDG-PET/CT in distinguishing benign neurofibroma from MPNST. A 6-year-old male patient who had NF1 admitted to emergency service due to high fever. Acute upper respiratory tract infection was diagnosed; antipyretic and abundant fluid intake was suggested. When high fever continued, the patient referred to our hospital on detection of axillary lymphadenopathy. Leukocytosis was detected in patient's blood count. Sedimentation was 54 mm/h, C-reactive protein 166 g/L, and lactate dehydrogenase 276U/L. Blood and throat cultures did not show pathogenic bacteria. In serological tests, VZV-IgG, EBV-VCA-IgG, and CMV-IgG were avidite positive; Hepatitis B Ag, Anti-HIV, Anti-HAV IgG and IgM, Anti-HCV, EBV-VCA IgM, and VZV-IgM were negative. Based on these results, cervical and thoracic contrast-enhanced computed tomography was performed on preliminary diagnosis of MPNST. Solid lesions with rounded margins, large one being 49 mm in size, that extend from superior mediastinum to posterior mediastinum, left axillary region, and left part of neck were detected, and they were surrounding the vascular structures. Since neurofibroma, MPNST, and lymphoma could not be distinguished, patient referred to FDG-PET/CT scanning. In FDG-PET/CT, highest lesion maximum standardized uptake value (SUVmax) was 1.5; SUVmaxlesion/SUVmaxliver 1.0, and SUVmax/ SUV mean liver 1.5. Biopsy from mediastinal and axillary region did not have LN structure and was positive for S-100 immunostaining, and patient was diagnosed as benign neurofibroma. We believe that there is no need for biopsy in lesions considered benign based on FDG-PET/CT parameters.http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_11_18malignant peripheral nerve sheath tumorneurofibromatosispositron-emission tomography/computed tomography
spellingShingle Fikri Selcuk Simsek
Saadet Akarsu
Yavuz Narin
Can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive sampling
World Journal of Nuclear Medicine
malignant peripheral nerve sheath tumor
neurofibromatosis
positron-emission tomography/computed tomography
title Can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive sampling
title_full Can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive sampling
title_fullStr Can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive sampling
title_full_unstemmed Can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive sampling
title_short Can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive sampling
title_sort can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive sampling
topic malignant peripheral nerve sheath tumor
neurofibromatosis
positron-emission tomography/computed tomography
url http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_11_18
work_keys_str_mv AT fikriselcuksimsek canwedifferentiatemalignantperipheralnervesheathtumorfrombenignneurofibromawithoutinvasivesampling
AT saadetakarsu canwedifferentiatemalignantperipheralnervesheathtumorfrombenignneurofibromawithoutinvasivesampling
AT yavuznarin canwedifferentiatemalignantperipheralnervesheathtumorfrombenignneurofibromawithoutinvasivesampling